BDNF Signaling in Vascular Dementia and Its Effects on Cerebrovascular Dysfunction, Synaptic Plasticity, and
1Department of Anatomy, Chonnam National University Medical School, Hwasun, Korea.
Journal of Lipid and Atherosclerosis
|June 3, 2024
Summary
Low serum levels of Brain-Derived Neurotrophic Factor (BDNF) are linked to Vascular Dementia (VaD). Understanding BDNF
Area of Science:
- Neuroscience
- Neurology
- Biochemistry
Background:
- Vascular Dementia (VaD) is the second leading cause of dementia, marked by cognitive deficits and neuropathological changes.
- Brain-Derived Neurotrophic Factor (BDNF) plays crucial roles in neuronal survival, synaptic plasticity, and cognitive function.
- Reduced serum and cerebrospinal fluid BDNF levels are observed in VaD patients, suggesting its involvement in the disease.
Purpose of the Study:
- To review the current understanding of BDNF signaling's role in the neuropathology of Vascular Dementia.
- To explore how BDNF influences key pathological processes in VaD, including cerebrovascular dysfunction, synaptic impairment, and cholinergic deficits.
Main Methods:
- Literature review of existing studies on BDNF and Vascular Dementia.
- Analysis of research investigating BDNF levels and signaling pathways in VaD patients and models.
Main Results:
- Patients with VaD exhibit significantly lower serum BDNF levels compared to healthy individuals.
- BDNF deficiency is identified as a key indicator of VaD.
- BDNF signaling is implicated in cerebrovascular dysfunction, synaptic impairment, and cholinergic system abnormalities in VaD.
Conclusions:
- BDNF plays a critical role in the neuropathology of Vascular Dementia.
- BDNF levels serve as an important biomarker for VaD.
- Targeting BDNF signaling pathways may offer therapeutic strategies for preventing and treating VaD.
Related Concept Videos
Notch Signaling Pathway
4.2K
The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.2K
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
The Blood-brain Barrier
47.2K
Overview
47.2K
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120


